Intema Seeks High Court Review Of Nixed Fetal Test Patent

Law360, Los Angeles (May 30, 2013, 4:29 PM EDT) -- Intema Ltd. has asked the U.S. Supreme Court to review a Federal Circuit decision nixing its patent on a fetal Down syndrome screening test, saying if the decision isn't reversed it will render most diagnostic, screening and personal medicine tests unpatentable.

The May 14 petition comes after the Federal Circuit, citing the Supreme Court's Mayo v. Prometheus decision, ruled in November that an Intema patent for the test isn't patent-eligible because it claims both an abstract idea and a law of nature, reversing a lower court's...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.